Opens in a new tab
Lean Seal ISO website iv removebg
ALWAYS AUDIT READY
Feasibility Inquiry

Patient Recruitment, Addressing Diversity and Other Challenges

Patient Recruitment
Share

Clinical trials move fast in today’s complex research environment. Recruiting eligible and suitable patients is increasingly challenging in the face of more complex trial protocols, with stricter eligibility criteria.

At the same time patient recruitment is ever more challenging and competitive, diversity in clinical trials is critical to ensure the scientific integrity, ethical conduct, and societal impact of research efforts. Adding to the complexity of this task diversity is not limited to demographic differences in race, ethnicity, sex, gender identity, sexual orientation, age, socioeconomic status, physical abilities, religious beliefs, political beliefs, and educational background; diversity also encompasses professional, cognitive, family structure, cultural, and geographic differences.

Recruitment difficulties remain one of the main causes of clinical trial delays. A significant share of trials struggle to reach their enrollment targets, and in oncology it is common for sites to enroll only a handful of patients, or none at all. For sponsors, that makes where you place your trial, and who helps you choose the sites, a decisive factor.

Well-framed, objective criteria maintain the integrity of a study. The process of reviewing a candidate against the inclusion and exclusion criteria of the trial, known as subject screening, determines their eligibility. Currently there is no uniform reporting protocol to support universally consistent stats on screen failure prevalence. However, an audit of 15 randomized oncology trials at a cancer centre in India found that the largest cause of screen failure was ‘not meeting the inclusion criteria’ (54.9% of screen failures).1 Wherein the screen failure rate formula takes the number of ineligible candidates divided by the number of screened candidates multiplied by 100 to get screen failure rate as a percentage overall.

Demographics Vary from Region-to-Region

Across the entire U.S. system, the estimated participation rate to cancer treatment trials is 7.1%.2 Black or African Americans in the U.S. represent about 13.5% of the population (about 15% Scimega Canadian Oncology CROincluding people who identify as Black in combination with another race).3 Yet they made up only 8% of participants in the trials supporting FDA’s 2020 novel drug approvals.4 Similarly, Hispanic or people of Latin descent represented 11% of participants in those trials, versus about 20% of the U.S. population.3,4

Racialized people are projected to make up 38% to 43% of the Canadian population by 2041.5 Such a diverse population combined with a universal healthcare system for all Canadian citizens offers a compelling opportunity for cutting-edge oncology biotechs striving to ensure global trials get the right mix of participants for their clinical trials.

 

In Australia an estimated 5% of adult cancer patients participate in clinical trials, a rate that has barely moved in two decades, and participation is lower among migrants, people whose main language is not English, older patients and those living in regional areas.6

Large numbers of people of color in the U.S. have no — or reduced — access to healthcare. As a result, they lack the opportunity to learn about clinical trials and how they can benefit by participating. Clinical trials often take place at the most advanced U.S. research institutions, where doctor-patient conversations for people of color do not frequently take place.

How Does Canada Differ?

Canada has one of the most diverse populations in the world and boasts the highest percentage of foreign-born residents among G7 countries7. A diverse population combined with a universal healthcare system for all Canadian citizens offers a compelling opportunity for cutting-edge U.S. biotechs striving to ensure global trials get the right mix of participants.

Canadian sites have a strong track record of meeting their recruitment commitments, and leading cancer centres enroll a meaningful share of their patients in clinical Scimega Canadian Oncology CROtrials. With sites in about 5% of all ongoing interventional trials worldwide, Canada is fourth in its number of clinical trials sites and is the G7 leader in clinical trial productivity (number of trials/population)8,9. In addition, the nation is globally recognized for the quality and expertise of its research clinicians, many of whom are globally recognized for major medical discoveries and innovations, and its ability to conduct clinical research in complex therapeutic areas with diverse population bases.

Immigrants in Canada represented 23% of the total Canadian population in 2021, the highest proportion among G7 countries.7

 

The advantage of universal health care in Canada means that citizens and permanent residents are covered for medically necessary hospital and physician services, regardless of income, employment, health or age, and the system is funded through taxes.10

In Canada cancer patients are funneled through select oncology health centers across the country and will typically receive treatment at the same center throughout the evolution of their disease (1st, 2nd line, 3rd line, etc). A factor that greatly aids in identification of possible oncology trial participants.

Attaining diversity – How We Do It

For sponsors to attain it ‘diversity’ must be unequivocally defined by your team for each clinical trial. More specifically defining diversity is best undertaken within the context of site selection strategy. And, most importantly you must determine if you will keep track of it during enrollment, and if so, how.

Only CROs, like Scimega in Canada, with the necessary bandwidth for sites within their region and specialization have the capacity to provide sponsors with the ability to effectively include defined, measurable diversity targets into the feasibility approach and site selection strategy for your trial.

This means the CRO acts very much like a SMO in regard to communication and relationships with sites and is equipped to share hard data for the measurable diversity indicators sought for your trial; has strong site relationships to access this data from sites; can confirm established, repeat experience with a wide range of sites in the region; and that all data provided can be cross-referenced with existing public stats.

Site Selection – How To Incorporate Diversity Into Your Strategy

Key elements to look for from your potential CRO when it comes to attaining diversity targets for your global trial in any specific region include:

  • During the bid defense and trial kick-off your vendor should push the door wide-open on the topic of diversity to clarify your expectations and targets as the trial sponsor;
  • Seek specifics on how the vendor will roll your diversity targets into the site identification strategy;
  • Look for confirmations from the vendor of prior experience, number of sites to contact, hard data derived through questions to sites about patient populations and time frames, that are cross-referenced with existing public stats.

Sites do have stats on diversity indicators such as race, albeit stats on these indicators may reside within different departments of the hospital such as medical records, pharmacy, research units, and elsewhere. Access to reliable data requires cross-functional corroboration on the part of the CRO seeking to determine site capacities to fulfill diversity targets for your trial. To do so, solid site relationships are a must to access this data quickly and efficiently from a wide range of sites in a particular region.

Part of attaining trial participant diversity is cultural. Which is why your vendor also needs to be proactive and alert to all current health care players in their region such as patient advocacy groups and emerging regional research centers. Patient advocacy groups can become a useful ally and sometimes release information about a trial through channels that are more readily accessible to a particular non-traditional patient population that you may seek for your trial.

Real-Time Feasibility Assessment Data Leads To Faster Recruitment

Real-time data for a real-world pace doesn’t just improve efficiency—it can improve the entire prospect for successful study outcomes when it matters most.

Missing crucial enrollment deadlines is a top concern.

  • Many U.S. sites report that recruitment pressures limit how many new studies they can take on.

Real-time feasibility assessment data can improve the entire prospect for successful study outcomes by supporting: Faster decisions; More robust expansion planning; and Better support choices between regions.

Sometimes a global group or the sponsor may not have depth of site relationships in a region of interest. A regional partner that can readily link you quickly and efficiently to the people that could be interested in your trial is tantamount to gaining access to real-time feasibility assessment data. Critical feedback to best assess that the region under consideration is going to do what you want it to do. To be of real value your partner should be able to deliver this within two weeks.

It’s not a process that should be taking 4-6 months if your partner has the proper relationships for their network of sites in that region. Key to this is the consideration that they are looking at a real-time feasibility assessment of the region for you and are aware of the competing trials. The ones that are enrolling right now. As these will be your greatest impediment to site recruitment.

Canada runs more ongoing clinical trials per capita than any other G7 country8, which means its sites, investigators and research ethics boards are highly experienced in running complex global oncology studies. In such an active research environment, knowing which sites have capacity, and which are free of competing studies right now, is what separates fast enrollment from slow. That’s where Scimega’s real-time feasibility comes in. And across the country, Canada’s regional cancer centres serve large patient populations, so there is room for new studies when sites are chosen well.

This means the data you’re presented should be very fresh. And your partner should be able to provide this data with no more than a one-month time stamp reporting on the interest and availability for each of the sites they recommend to you. Especially if you’re in an early phase, and you’re trying to move from escalation to expansion. You don’t have the luxury of time.

The high level of recruitment success in Canada is the result of a few key factors: universal, publicly funded access to healthcare; a diverse patient population; a more positive public perception of clinical trials than in other regions; and a vast national network for disease treatment.

Canada has one of the most diverse populations in the world and is associated with the production of top-quality data in global studies. Scimega’s active network is composed of fifty oncology clinical research centers, with top global talent that foster this country’s solid reputation for research in clinical medicine, biomedicine, and science and technology.

While the landscape in Canada is generally quite favorable to the success of global studies, this isn’t an exhaustive list of the factors that make Canadian PIs some of the top patient enrollers, nor does it always translate into enrollment success for every study.

Unsurprisingly, enrollment success can vary from study-to-study, which is why it is vital for clinical trial sponsors to be selective about who they partner with to attain the right mix of patients for their global studies. A specialized CRO, like Scimega, with local expertise that can leverage the disease treatment networks effectively are often most successful at connecting Canadian PIs to the most relevant studies for the patient population they serve.

Interested in Learning More About the Canadian Opportunity?

At Scimega, we are proud to report that the sites and Canadian PIs we work with are often top enrollers in the global oncology studies on which we collaborate with sponsors. In fact, 95% of the sites we recommend for selection on the trials we undertake meet their enrollment targets, and the majority of sites we recommend, activate and oversee go on to surpass them.11

As a niche Canadian CRO acting in Canada for the conduct of global cutting-edge oncology trials sponsored by mid-size and smaller biotechs, our oncology experts work with your team to devise innovative solutions specific to the unique challenges of your oncology clinical trial.

For some biotechs that are smaller, it can be daunting to consider a multi vendor model because you may think we don’t have the money, or we don’t have the bandwidth to manage more than one CRO. In fact, if you select specialized regional vendors with an established, broad site network, with a team experienced in your therapeutic area, that is open minded, collaborative and have a proven experience meshing with other teams this can really help you overcome recruitment obstacles and better align to attain the goals of your trial than may be possible with  a single centralized CRO partner.

With over a quarter of a century proven track record of unparalleled Canadian oncology experience Scimega guarantees sponsors the quickest site start-up and highest patient recruitment rate, without sacrificing premium quality data. With an optimal operations design robust enough to address an ever-changing clinical trial landscape.

If you’re interested in learning more about the Canadian opportunity, explore an expansion with us!

Scimega Canadian Oncology CROContributed by: Julie Martin, CEO & co-Owner

 

References

  1. Parekh et al. Audit of screen failure in 15 randomised studies from a low and middle-income country. ecancermedicalscience. 2022;16:1476. (Single-centre audit, Tata Memorial Centre, Mumbai.)
  2. Unger JM, Shulman LN, Facktor MA, Nelson H, Fleury ME. National estimates of the participation of patients with cancer in clinical research studies based on Commission on Cancer accreditation data. J Clin Oncol. 2024;42:2139–2148. (Data from 2013–2017.)
  3. U.S. Census Bureau. QuickFacts: United States, Vintage 2025 population estimates (https://www.census.gov/quickfacts/fact/table/US/RHI225224); and Facts for Features: Black History Month, February 2024 (Black alone or in combination population, 2022).
  4. U.S. Food and Drug Administration. 2020 Drug Trials Snapshots Summary Report. https://www.fda.gov/media/145718/download
  5. Statistics Canada. Canada in 2041: A larger, more diverse population with greater differences between regions. The Daily, September 8, 2022.
  6. You et al. Factors that influence clinical trial participation for oncology patients in Australia: a scoping review. BMJ Open. 2025;15:e095355.
  7. Statistics Canada. Immigrants make up the largest share of the population in over 150 years and continue to shape who we are as Canadians. The Daily, October 26, 2022.
  8. Innovative Medicines Canada. Clinical Trials in Canada: Insights and Implications. Research Note, July 2025. https://innovativemedicines.ca/wp-content/uploads/2025/07/6785_IMC_2025ResearchNote_ClinicalTrialsCanada_eng_final.pdf
  9. Invest in Canada. Clinical trials. https://www.investcanada.ca/industries/clinical-trials
  10. Immigration, Refugees and Citizenship Canada. Health care in Canada: Canada’s universal health-care system. https://www.canada.ca/en/immigration-refugees-citizenship/services/new-immigrants/new-life-canada/health-care/universal-system.html
  11. Scimega Research Inc. Internal performance data: enrollment against target for sites recommended, activated and overseen by Scimega.